The steady-state pharmacokinetics of cefepime were evaluated in 10 middle-aged and elderly patients with acute lower respiratory tract infections who were receiving 1 g intravenously every 12 h. One preinfusion and 15 postinfusion serum samples and total urine output were collected over one dosing interval between days 3 and 8 of therapy. Cefepime concentrations in serum over time exhibited a multicompartmental profile. Peak and trough concentrations in serum determined by a validated high-performance liquid chromatography method were 71.2 ± 17.2 (mean ± standard deviation) and 6.0 ± 4.9 mg/liter, respectively. The steady-state volume of distribution was 0.22 ± 0.05 liter/kg. Elimination half-lives ranged from 1.93 to 6 .04 h (3.92 ± 1.28 h), and total body clearances ranged from 36.9 to 102 ml/min per 1.73 m2 (73.0 ± 19.7 ml/min per 1.73 m2). The disposition of cefepime at steady state in patients was comparable to previous observations in healthy elderly volunteers. The predictive performance of regression equations derived from single-dose studies in volunteers relating creatinine clearance with total body and renal clearances of cefepime exhibited slight biases (mean predictive errors, -9.7 and 2.1 ml/min per 1.73 m2, respectively) and similar precisions. Predicted and observed total body clearances (63.3 ± 25.1 versus 73.0 ± 19.7 ml/min per 1.73 m2, respectively) and renal clearances (51.3 ± 24.4 versus 49.3 ± 19.6 ml/min per 1.73 m2, respectively) were not significantly different. The pharmacokinetics of cefepime in infected patients appeared to be unaltered by illness, and the steady-state disposition of cefepime was predictable from data derived from single-dose studies in volunteers.
Cefepime is an investigational cephalosporin which, in comparison with currently marketed extended-spectrum agents, demonstrates increased coverage against gram-positive organisms while retaining a broad spectrum of activity against gram-negative organisms. Against members of the family Enterobacteriaceae, MICs for 90% of strains are generally <0.5 mg/liter, against Pseudomonas aeruginosa they are <8 mg/liter, and against Staphylococcus aureus they are <4 mg/liter (6, 15, 16 While those investigations involved noninfected volunteers who were evaluated following single-dose administra-tion, the ultimate recipients of an intravenous antibiotic are hospitalized patients who receive maintenance-dose therapy for the treatment of infections. Pharmacokinetic parameters derived from single-dose studies, however, do not always accurately predict multiple-dose disposition (8) . Moreover, the presence of an acute infection itself has been identified by some investigators as a factor which can significantly alter the pharmacokinetics of antibiotics (5, 7, 12) . Such an effect has not, however, been consistently observed (3, (9) (10) (11) . Inasmuch as the pharmacokinetics of cefepime have not been evaluated during maintenance-dose administration in older subjects or in patients with acute illnesses, this study was designed to characterize its disposition at steady state in middle-aged and elderly hospitalized patients being treated for respiratory tract infections. Furthermore, the accuracy with which the steady-state pharmacokinetics of cefepime in patients could be predicted from the relationships between CLCR and cefepime CL and CLR derived from studies in noninfected volunteers was assessed. A semilogarithmic plot of the cefepime serum concentration-versus-time data was multicompartmental for all patients (Fig. 1) . The corresponding pharmacokinetic parameters are displayed in Table 2 . Following a 1-g dose, the mean peak cefepime concentration in serum at the end of the infusion was 71.2 + 17.2 mg/liter, and the mean trough concentration 11.5 h after the end of the infusion was 6.0 ± 4.9 mg/liter. t /2 ranged from 1.93 to 6.04 h (3.92 ± 1.28 h), and V,. ranged Fig. 1 (11) .
MATERIALS AND METHODS
The regression equations relating renal function with cefepime CL and CLR derived from single-dose studies in volunteers performed well in predicting steady-state clearances in patients. A small negative bias was observed for the CL equation, and a slight positive bias was observed for the CLR equation; both, however, were less than 10 ml/min per 1.73 m 2. The equations demonstrated similar precision of approximately 20 ml/min per 1.73 M2. These relationships would therefore be useful in the clinical setting as the basis for dosage adjustment (13) for patients with impaired renal function who are receiving cefepime.
The results of this investigation suggest that the pharmacokinetics of cefepime during maintenance-dose therapy in middle-aged to elderly, hospitalized patients are consistent with values projected from single-dose investigations. Furthermore, acute illness does not appear to alter the disposition of cefepime significantly. Relationships between renal function indices and cefepime clearances derived from noninfected volunteers perform well in predicting the cefepime disposition during multiple-dose administration in infected patients.
